{
    "clinical_study": {
        "@rank": "35131", 
        "arm_group": [
            {
                "arm_group_label": "TA-8995 1 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "TA-8995 2.5 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "TA-8995 5 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "TA-8995 10 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "TA-8995 25 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo (TA-8995 1mg)", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Placebo (TA-8995 2.5mg)", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Placebo (TA-8995 5mg)", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Placebo (TA-8995 10mg)", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Placebo (TA-8995 25mg)", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety, tolerability, pharmacokinetics and\n      pharmacodynamics of TA-8995 after multiple doses in healthy adult male subjects"
        }, 
        "brief_title": "Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 After Multiple Doses in Healthy Subjects", 
        "completion_date": {
            "#text": "June 2010", 
            "@type": "Actual"
        }, 
        "condition": "Dyslipidemia", 
        "condition_browse": {
            "mesh_term": "Dyslipidemias"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Free from any clinically significant illness or disease as determined by their\n             medical history, physical examination, laboratory and other tests and as judged by\n             the Investigator.\n\n          -  Between 18 - 55 years old.\n\n          -  Male of Caucasian ethnic origin.\n\n          -  Body mass index (BMI) in the range of 19 - 33 kg/m\u00b2 and had a minimum weight of 50\n             kg. Subjects with a BMI in the range 30.0 - 33.0 kg/m\u00b2 had to have a waist\n             measurement of \u2264 91 cm.\n\n        Exclusion Criteria:\n\n          -  High density lipoprotein (HDL)-C level of greater or equal to 2.59 mmol/L (\u2265 100\n             mg/dL) at Screening.\n\n          -  Abnormal Electrocardiogram (ECG) at Screening or Day -1 including a QTc \u2265 430 ms (The\n             QTc-interval was calculated automatically according to Bazett's formula. In the case\n             of results of \u2265 430 ms, QTc was additionally calculated manually using Fridericia's\n             formula which was used as an exclusion criterion).\n\n          -  Family history of long QT syndrome, hypokalaemia or Torsades de Pointes\n\n          -  Impaired endocrine, thyroid, hepatic, respiratory or renal function, diabetes\n             mellitus, coronary heart disease or history of any psychotic illness\n\n          -  Presence or history of gastro-intestinal, hepatic or renal disease or any other\n             condition known to interfere with the absorption, distribution, metabolism or\n             excretion of drugs"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "61", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01879020", 
            "org_study_id": "TA-8995-E02"
        }, 
        "intervention": [
            {
                "arm_group_label": "TA-8995 1 mg", 
                "description": "Drug: TA-8995 1mg", 
                "intervention_name": "TA-8995", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "TA-8995 2.5 mg", 
                "description": "Drug: TA-8995 2.5mg", 
                "intervention_name": "TA-8995", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "TA-8995 5 mg", 
                "description": "Drug: TA-8995 5mg", 
                "intervention_name": "TA-8995", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "TA-8995 10 mg", 
                "description": "Drug: TA-8995 10mg", 
                "intervention_name": "TA-8995", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "TA-8995 25 mg", 
                "description": "Drug: TA-8995 25mg", 
                "intervention_name": "TA-8995", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo (TA-8995 1mg)", 
                "description": "Placebo (TA-8995 1mg)", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo (TA-8995 2.5mg)", 
                "description": "Placebo (TA-8995 2.5mg)", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo (TA-8995 5mg)", 
                "description": "Placebo (TA-8995 5mg)", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo (TA-8995 10mg)", 
                "description": "Placebo (TA-8995 10mg)", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo (TA-8995 25mg)", 
                "description": "Placebo (TA-8995 25mg)", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "MT-8995", 
            "Dyslipidemia", 
            "Cholesteryl ester transfer proteins"
        ], 
        "lastchanged_date": "June 12, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Hamburg", 
                    "country": "Germany", 
                    "zip": "22769"
                }, 
                "name": "Momentum Pharma Services GmbH"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "10", 
        "official_title": "A Randomised Double-blind, Placebo-controlled, Ascending-dose, Phase I Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 After Multiple Doses in Healthy Adult Male Subjects", 
        "overall_official": {
            "affiliation": "Momentum Pharma Services GmbH", 
            "last_name": "Werner Weber, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of participants with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "336 hours post dose"
            }, 
            {
                "measure": "Laboratory tests (haematology, biochemistry and urinalysis)", 
                "safety_issue": "Yes", 
                "time_frame": "336 hours post dose"
            }, 
            {
                "measure": "Vital signs (supine systolic and diastolic blood pressure, heart rate and body temperature)", 
                "safety_issue": "Yes", 
                "time_frame": "336 hours post dose"
            }, 
            {
                "measure": "Area under the plasma concentration (AUC) versus time curve over the final dosing interval (AUC0-\u03c4, Steady-state)", 
                "safety_issue": "No", 
                "time_frame": "7 days post the final dose"
            }, 
            {
                "measure": "The last time point 't' with a concentration Ct \u2265 Lower limit quantification (LLQ) (AUC0-t, Steady-state)", 
                "safety_issue": "No", 
                "time_frame": "7 days post the final dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01879020"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Cholesterol ester transfer protein (CETP) activity (%)", 
                "safety_issue": "No", 
                "time_frame": "7 days post the final dose"
            }, 
            {
                "measure": "CETP concentration (mg/mL)", 
                "safety_issue": "No", 
                "time_frame": "4 hours after the first and the fibal dose"
            }
        ], 
        "source": "Mitsubishi Tanabe Pharma Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mitsubishi Tanabe Pharma Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}